



Attorney Docket No. 23100.64
Customer No. 000027683

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

McAnalley et al.

Application No. 10/797,344

Filed: March 10, 2004

For: COMPOSITIONS OF PLANT
CARBOHYDRATES AS
DIETARY SUPPLEMENTS

§
§
§
§
§
§
§
§
§
§

Confirmation No.: 4291

Group Art Unit: 1655

Examiner: Michele Flood

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on

12/7/2005

Ellen Lovelace

Ellen Lovelace

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in numerical order and are not in any order based on their pertinence.

The information contained in this Fifth Supplemental Information Disclosure Statement was submitted to the Canadian Intellectual Property Office under Section 34.1 of the Canadian Patent Act in connection with Applicant's Canadian Patent Application No. 2,262,972 by J. Kevin Wright of Davis & Company on behalf of Micro Health Solutions on October 7, 2005. A copy of the cover letter by which Davis & Company submitted the information to the Canadian Patent Office on October 7, 2005 is enclosed. Applicant became aware of the information submitted by Davis & Company by virtue of the notice that was mailed to Applicant's Canadian representative on October 20, 2005, a copy of which is also enclosed. The submission filed by Davis & Company included many references that were previously disclosed in this application pursuant to a Supplemental Information Disclosure Statement filed on July 6, 2004. The information submitted with this Fifth Supplemental Information Disclosure Statement includes only the information in the submission filed by Davis & Company that was not already of record in this application.

12/13/2005 GWORDF1 00000017 10797344

01 FC:1806

180.00 OP


This Fifth Supplemental Information Disclosure Statement is being filed after the mailing date of a Final Action under 37 CFR §1.113.

It is hereby certified that each item of information contained in this Fifth Supplemental Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Fifth Supplemental Information Disclosure Statement. A copy of that communication is submitted herewith (37 CFR §1.97 (e)(1)).

Accompanying this transmittal is the \$180.00 fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement Under 37 CFR §1.97(d).

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.


Respectfully submitted,



Randall C. Brown
Registration No. 31,213

Dated: 12/7/05

HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 214.651.5242
Facsimile: 214.200.0853
File: 23100.64
D-1395053.1



In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/797,344
				Filing Date	March 10, 2004
				Applicant(s)	McAnalley et al.
				Art Unit	1655
				Examiner Name	Michele Flood
				Attorney Docket Number	23100.64
SHEET	1	OF	1		

U. S. PATENT DOCUMENTS				
Examiner's Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N

NON-PATENT LITERATURE DOCUMENTS		
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item, date, page(s), volume- issue number(s), publisher, city/country where published
	A1	B. THORNTON, et al.; <i>Analysis of the Sugar Specificity and Molecular Location of the B-Glucan-Binding Lectin Site of Complement Receptor Type 3 (CD11b/CD18)</i> ; The Journal of Immunology, 1996, pp. 1235-1246
	A2	L.S. KIND, et al.; <i>Enhanced Vascular Permeability Induced in Mice by Larch Arabinogalactan</i> ; Immunology, 1970, 19, pp. 799-807
	A3	J.N. LIU, et al.; <i>B Cell Stimulating Activity of Seaweed Extracts</i> ; Int. J. Immunopharmac. Vol. 19, No. 3, pp. 135-142, 1997
	A4	C. BLONDIN, et al.; <i>Inhibition of Complement Activation by Natural Sulfated Polysaccharides (Fucans) From Brown Seaweed</i> ; Molecular Immunology, Vol. 31, No. 4, pp. 247-253, 1994
	A5	E. FURUSAWA, et al.; <i>Antitumor Potential of Low-Dose Chemotherapy Manifested in Combination with Immunotherapy of Viva-Natural, a Dietary Seaweed Extract, on Lewis Lung Carcinoma</i> ; Cancer Letters, 50 (1990), pp. 71-78
	A6	G. HOMANN, et al.; <i>Mannan-Binding Protein and Complement Dependent Opsonization in Alcoholic Cirrhosis</i> ; Liver 1995, 15, pp. 39-44
	A7	A.C. MANN, et al.; <i>Monosaccharide Composition of Haptoglobin in Liver Diseases and Alcohol Abuse: Large Changes in Glycosylation Associated with Alcoholic Liver Disease</i> ; Clinica Chimica Acta 227 (1994) pp. 69-78
	A8	H. STIBLER, et al.; <i>Evidence of a Reduced Sialic Acid Content in Serum Transferrin in Male Alcoholics</i> ; Alcoholism: Clinical and Experimental Research, Vol. 5, No. 4, Fall 1981, pp. 545-549
	A9	F. BEAUGE, et al.; <i>Abnormal Fluidity and Surface Carbohydrate Content of the Erythrocyte Membrane in Alcoholic Patients</i> ; Alcoholism: Clinical and Experimental Research, Vol. 9, No. 4, July/August 1985; pp. 322-326

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.